PURPOSE OF THE RESEARCH: VAR2CSA is considered as the main target of protective immunity against pregnancy-associated malaria. VAR2CSA high molecular weight complicates scaling up production of VAR2CSA recombinant protein for large-scale vaccination programmes. We previously demonstrated that antibodies induced by NTS-DBL1X-Id1-DBL2X efficiently block parasite binding to CSA in a similar manner to antibodies induced by the full-length extracellular part of VAR2CSA. In order to identifying the shortest fragment of VAR2CSA carrying major protective epitopes able to elicit inhibitory antibodies, we performed a refined antigenic mapping of NTS-DBL1X-Id1-DBL2X through a DNA vaccination technique. PRINCIPAL RESULTS: Five single or double domains constructs encoding NTS-DBL1X, NTS-DBL1X-Id1, Id1, Id1-DBL2X and DBL2X were made and used to immunize mice. The NTS-DBL1X, NTS-DBL1X-Id1, and Id1-DBL2X fragments all raised high titer immune response, as measured by ELISA. The DBL2X fragment raised a weaker antibody titer, and the Id1 construct failed to elicit antibody. Sera from mice immunized with NTS-DBL1X or DBL2X constructs failed to block infected erythrocytes binding to CSA, whereas sera from mice immunized with NTS-DBL1X-Id1 showed partial inhibitory activity, and the Id1-DBL2X fragment elicited antisera that totally abrogated infected erythrocytes adhesion to CSA. IgG purified from Id1-DBL2X antisera showed a similar inhibitory profile than Id1-DBL2X antisera. Anti-FCR3 anti-Id1-DBL2X antibodies also efficiently block the adhesion of erythrocytes infected by the HB3 parasite line to CSA. Id1-DBL2X antisera recognized the surface of field isolates from pregnant women, and inhibited CSA-binding of all 8 isolates tested, although to a variable level. MAJOR CONCLUSIONS: We raised high-titer antibodies against several parts of the protein, and identified Id1-DBL2X as the minimal VAR2CSA fragment inducing antibodies with CSA-binding inhibitory efficiency in the same range as the full-length extracellular part of VAR2CSA.
PURPOSE OF THE RESEARCH: VAR2CSA is considered as the main target of protective immunity against pregnancy-associated malaria. VAR2CSA high molecular weight complicates scaling up production of VAR2CSA recombinant protein for large-scale vaccination programmes. We previously demonstrated that antibodies induced by NTS-DBL1X-Id1-DBL2X efficiently block parasite binding to CSA in a similar manner to antibodies induced by the full-length extracellular part of VAR2CSA. In order to identifying the shortest fragment of VAR2CSA carrying major protective epitopes able to elicit inhibitory antibodies, we performed a refined antigenic mapping of NTS-DBL1X-Id1-DBL2X through a DNA vaccination technique. PRINCIPAL RESULTS: Five single or double domains constructs encoding NTS-DBL1X, NTS-DBL1X-Id1, Id1, Id1-DBL2X and DBL2X were made and used to immunize mice. The NTS-DBL1X, NTS-DBL1X-Id1, and Id1-DBL2X fragments all raised high titer immune response, as measured by ELISA. The DBL2X fragment raised a weaker antibody titer, and the Id1 construct failed to elicit antibody. Sera from mice immunized with NTS-DBL1X or DBL2X constructs failed to block infected erythrocytes binding to CSA, whereas sera from mice immunized with NTS-DBL1X-Id1 showed partial inhibitory activity, and the Id1-DBL2X fragment elicited antisera that totally abrogated infected erythrocytes adhesion to CSA. IgG purified from Id1-DBL2X antisera showed a similar inhibitory profile than Id1-DBL2X antisera. Anti-FCR3 anti-Id1-DBL2X antibodies also efficiently block the adhesion of erythrocytes infected by the HB3 parasite line to CSA. Id1-DBL2X antisera recognized the surface of field isolates from pregnant women, and inhibited CSA-binding of all 8 isolates tested, although to a variable level. MAJOR CONCLUSIONS: We raised high-titer antibodies against several parts of the protein, and identified Id1-DBL2X as the minimal VAR2CSA fragment inducing antibodies with CSA-binding inhibitory efficiency in the same range as the full-length extracellular part of VAR2CSA.
Authors: Andreea Waltmann; Jaymin C Patel; Kyaw L Thwai; Nicholas J Hathaway; Christian M Parobek; Achille Massougbodji; Nadine Fievet; Jeffery A Bailey; Philippe Deloron; Jonathan J Juliano; Nicaise Tuikue Ndam; Steven R Meshnick Journal: Am J Trop Med Hyg Date: 2018-01 Impact factor: 2.345
Authors: Thomas M Clausen; Stig Christoffersen; Madeleine Dahlbäck; Annette Eva Langkilde; Kamilla E Jensen; Mafalda Resende; Mette Ø Agerbæk; Daniel Andersen; Besim Berisha; Sisse B Ditlev; Vera V Pinto; Morten A Nielsen; Thor G Theander; Sine Larsen; Ali Salanti Journal: J Biol Chem Date: 2012-05-08 Impact factor: 5.157
Authors: Justin Doritchamou; Audrey Sabbagh; Jakob S Jespersen; Emmanuelle Renard; Ali Salanti; Morten A Nielsen; Philippe Deloron; Nicaise Tuikue Ndam Journal: PLoS One Date: 2015-09-22 Impact factor: 3.240
Authors: Anna Babakhanyan; Rose G F Leke; Ali Salanti; Naveen Bobbili; Philomina Gwanmesia; Robert J I Leke; Isabella A Quakyi; John J Chen; Diane Wallace Taylor Journal: PLoS One Date: 2014-02-04 Impact factor: 3.240
Authors: Mark A Travassos; Drissa Coulibaly; Jason A Bailey; Amadou Niangaly; Matthew Adams; Myaing M Nyunt; Amed Ouattara; Kirsten E Lyke; Matthew B Laurens; Jozelyn Pablo; Algis Jasinskas; Rie Nakajima; Andrea A Berry; Shannon Takala-Harrison; Abdoulaye K Kone; Bourema Kouriba; J Alexandra Rowe; Ogobara K Doumbo; Mahamadou A Thera; Miriam K Laufer; Philip L Felgner; Christopher V Plowe Journal: Am J Trop Med Hyg Date: 2015-04-27 Impact factor: 2.345
Authors: Eduard Rovira-Vallbona; Isadora Monteiro; Azucena Bardají; Elisa Serra-Casas; Daniel E Neafsey; Diana Quelhas; Clarissa Valim; Pedro Alonso; Carlota Dobaño; Jaume Ordi; Clara Menéndez; Alfredo Mayor Journal: PLoS One Date: 2013-07-25 Impact factor: 3.240